University Hospital of Basel

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

• University Hospital Basel

  Basel, 4031

  123 trials

• Universitätsspital Basel

  Basel, 4031

  87 trials

• Universitaetsspital Basel

  Basel, 4031

  33 trials

• Basel University Hospital

  Basel, Canton of Basel-City 4031

  6 trials

• University Hospital of Basel

  Basel, 4031

  6 trials

• University Hospital Basel, Department of Neurology

  Basel, 4031

  5 trials

• Department of Neurology, University Hospital Basel

  Basel, Canton of Basel-City 4056

  2 trials

  • NCT05029414EnDovascular Therapy Plus Best Medical Treatment (BMT) Versus BMT Alone for MedIum VeSsel Occlusion sTroke

  • NCT02756091International Intracranial Dissection Study

    Contact: Engelter Stefan, Prof. Dr. med. (principal investigator)

• Department of Neurosurgery, University Hospital of Basel

  Basel, 4031

  2 trials

  • NCT06488248Endoscopic Third Ventriculostomy vs. Ventriculoperitoneal Shunt in Idiopathic Normal Pressure Hydrocephalus (ENDOVEST)

    Contact: Florian Marc Ebel, Dr. med.

  • NCT04450797Intraoperative Ultrasound Guided Compared to Stereotactic Navigated Ventriculoperitoneal Shunt Placement

• Universitaetsspital Basel - Zentrum fur Hamato-Onkologie

  Basel

  2 trials

  • NCT06932562A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

    Contact: Heim

  • NCT05257083A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

• University Hospital Basel, Division of Internal Medicine

  Basel, 4031

  2 trials

  • NCT05145283Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation

  • NCT05127980Occurrence of Antibodies Cross-reacting With Autoantigens in Primary EBV Infection

    Contact: Michael Osthoff, PD Dr. med.

• University Hospital Basel, Endocrinology, Diabetes and Metabolism

  Basel, 4031

  2 trials

  • NCT07555132Circulating Oxytocin Changes in Response to MDMA vs. Placebo in Adult Patients With Autism Spectrum Disorder and Matched Healthy Controls

    Contact: Mirjam Christ-Crain, Prof. Dr. med.

  • NCT05598008Effects of Glucagon-like-Peptide-1 Analogues on Sexuality

• Anaesthesiology, University Hospital Basel

  Basel, 4031

  1 trial

  • NCT05392452Fully Closed-Loop Insulin Delivery in Abdominal Surgery (CLAB)

• Cardiology/Electrophysiology, University Hospital Basel

  Basel, 4031

  1 trial

  • NCT03718364Swiss Atrial Fibrillation Pulmonary Vein Isolation Registry

    Contact: Michael Kuehne, MD

• Cardiology, University Hospital Basel

  Basel, 4031

  1 trial

  • NCT04000061Heart Failure-USB: Prediction and Progression

    Contact: Christian Mueller, Prof. Dr.

• Department Breast, Abdomen, Pelvis; Universitätsspital Basel

  Basel, 4031

  1 trial

  • NCT07546695Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11/MACRONAC Study

    Contact: Walter P. Weber, Prof. Dr. med.

• Department for Cardiac Surgery, University Hospital Basel

  Basel, 4031

  1 trial

  • NCT04595630Diagnostic and Prognostic Value of Cardiac Biomarkers for Early Coronary Bypass Occlusion in Patients Undergoing Coronary Revascularization

    Contact: Denis Berdajs, Prof.

• Department of Cardiac Surgery, University Hospital Basel

  Basel, 4031

  1 trial

  • NCT04964765The Basel CardioInsightTM - 3D Mapping Study

    Contact: David Santer, Dr. med.

• Department of Cardiology, University Hospital Basel

  Basel, 4031

  1 trial

  • NCT04809922Accuracy of Cardiac Wearables Devices to Detect Atrial Fibrillation

• Department of Dermatology, University Hospital Basel

  Basel, 4031

  1 trial

  • NCT04605822Melanoma Detection in Switzerland With VECTRA

• Department of Medical Oncology, University Hospital Basel

  Basel, Canton of Basel-City 4031

  1 trial

  • NCT06455917TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients

    Contact: David König, Dr. med.

• Department of Neuroradiology, University Hospital Basel

  Basel, 4031

  1 trial

  • NCT05504941Detection of an Endovascular Treatment Target in Patients With an Acute, Spontaneous Intracerebral Hemorrhage

    Contact: Alex Brehm, PhD

• Department of Visceral Surgery, University Hospital Basel

  Basel, 4031

  1 trial

  • NCT06801899ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer

    Contact: Prof. Dr. med Adrian Billeter

• Dept. of Neurology, Universitätsspital Basel

  Basel, 4031

  1 trial

  • NCT06100718Discovery of New Cancer in the 1-year Follow-up After Ischemic Stroke in Patients at Risk: The INVISIBLE-1 Study

    Contact: Mira Katan, MD

• Dermatology, University Hospital Basel

  Basel, 4031

  1 trial

  • NCT04359394International Rare And Severe Psoriasis Expert Network

    Contact: Alexander Navarini, Prof. Dr. med. Dr. sc. nat.

• Division of Clinical Epidemiology, University Hospital Basel, University of Basel

  Basel, 4001

  1 trial

  • NCT05596773Community-Based Chronic Disease Care in Rural Lesotho

    Contact: Niklaus Labhardt, Prof. Dr. med.

• Division of Hematology, Department of Internal Medicine, Basel University Hospital

  Basel, 4031

  1 trial

  • NCT02827617Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia

• Duplicate_Universitätsspital Basel /ID# 221261

  Basel, Canton of Basel-City 4031

  1 trial

  • NCT04468984Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

• Duplicate_Universitätsspital Basel /ID# 256509

  Basel, Canton of Basel-City 4031

  1 trial

  • NCT05215639A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets

• Lab for Exp Otoneurology, University Hospital Basel

  Basel, CH-4031

  1 trial

  • NCT02142946Quantified Balance Measures During Stance and Gait: Multiple Sclerosis Patients. A Longitudinal Clinical Study

    Contact: John HJ Allum, DSc

• MS Centre, Neurology, University hospital Basel

  Basel, Basel 4031

  1 trial

  • NCT07193602VR-based Dexterity Training in MS

    Contact: Marcus D'Souza, PD Dr. med.

• Universitaetsspital Basel (Site 0094)

  Basel, Canton of Basel-City 4031

  1 trial

  • NCT03820986Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

• Universitaetsspital Basel (Site 0554)

  Basel, Canton of Basel-City 4031

  1 trial

  • NCT03553836Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

• Universitaetsspital Basel (Site 1201)

  Basel, Canton of Basel-City 4031

  1 trial

  • NCT03711032Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

• Universitaetsspital Basel (Site 1900)

  Basel, Canton of Basel-City 4056

  1 trial

  • NCT03675737Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

• Universitaetsspital Basel (Site 2104)

  Basel, Canton of Basel-City 4031

  1 trial

  • NCT03516981A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

• Universitaetsspital Basel (Site 2602)

  Basel, Canton of Basel-City 4031

  1 trial

  • NCT04564547Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

• Universitaetsspital Basel (Site 3302)

  Basel, Canton of Basel-City 4031

  1 trial

  • NCT04223778Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)

• Universitätsspital Basel, Allergologie

  Basel, 4031

  1 trial

  • NCT05819463Treatment and Medical Care of Patients With Moderate-to-severe Atopic Dermatitis - TREATswitzerland

    Contact: Karin Hartmann, Prof. Dr. med.

• Universitätsspital Basel /ID# 201599

  Basel, Canton of Basel-City 4031

  1 trial

  • NCT03569293Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

• Universitätsspital Basel /ID# 224160

  Basel Town, Canton of Basel-City 4031

  1 trial

  • NCT04497597A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis

• Universitätsspital Basel /ID# 256677

  Basel Town, Canton of Basel-City 4031

  1 trial

  • NCT06068842A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer

• Universitätsspital Basel; Neurologie

  Basel, 4031

  1 trial

  • NCT00676715A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

• University Centre for Gastrointestinal and Liver Diseases, University Hospital Basel, Switzerland

  Basel, 4031

  1 trial

  • NCT06092385SASL Swiss Cirrhosis Cohort

    Contact: Christine Bernsmeier, Prof. Dr. med.

• University Heart Center Basel, University Hospital Basel

  Basel, Canton of Basel-City 4031

  1 trial

  • NCT07743697Comparing Suture vs. Combined Closure Strategies for Large Blood Vessel Access in Patients Undergoing Transcatheter Aortic Valve Implantation (TAVI)

    Contact: Max Wagener, MD, MSc

• University Hopital Basel

  Basel

  1 trial

  • NCT02902198Taste Physiology in Obese Volunteers Before and After Bariatric Surgery

    Contact: Bettina Wölnerhanssen, Dr

• University Hospital Basel, Angiology

  Basel

  1 trial

  • NCT04774159Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

    Contact: Ines Meurer

• University hospital Basel, Cardiovascular Research Institute of Basel (CRIB)

  Basel, Basel 4056

  1 trial

  • NCT06499519SpinChip Hs-cTnI Clinical Diagnostic Performance

• University Hospital Basel, Department of Cardiology

  Basel, 4031

  1 trial

  • NCT05662293Characterization of Arrhythmia-induced Cardiomyopathy

    Contact: Patrick Badertscher, MD

• University Hospital Basel, Department of Endocrinology

  Basel, Canton of Basel-City 4031

  1 trial

  • NCT05013957Neuroendocrine Neoplasms Methylation Based Classifier - The NEMESIs-study

• University Hospital Basel, Department of Interventional and Diagnostical Neuroradiology

  Basel, Canton of Basel-City 4031

  1 trial

  • NCT06472336IntraCranial Atherosclerosis Related Large-vessel Occlusion Treated With Urgent Stenting (ICARUS)

    Contact: Alex Brehm, PhD

• University Hospital Basel, Department of Neurology and Department of Biomedicine

  Basel, 4031

  1 trial

  • NCT04760990A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.

• University Hospital Basel, Department of Neurosurgery

  Basel, Canton of Basel-City 4031

  1 trial

  • NCT04997317Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide

    Contact: Damian Wild, Prof. Dr. med.

• University Hospital Basel, Department of Psychosomatic Medicine

  Basel, 4031

  1 trial

  • NCT05781893Basel Long COVID-19 Cohort Study and Digital Long COVID Substudy

• University Hospital Basel, Department of Radiology and Nuclear Medicine

  Basel, Canton of Basel-City 4031

  1 trial

  • NCT0645535861Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)

    Contact: Guillaume Nicolas, Dr.

• University Hospital Basel, Division of Clinical Epidemiology

  Basel, 4051

  1 trial

  • NCT05684055"Community-based, eHealth Supported Management of Cardiovascular Risk Factors by Lay Village Health Workers (ComBaCaL aHT TwiC 1 & ComBaCaL aHT TwiC 2)

• University Hospital Basel, Division of Hematology

  Basel, 4031

  1 trial

  • NCT04812483Immunomodulation With Eltrombopag in ITP

• University Hospital Basel, Division of Hematology or Medical Oncology

  Basel, Canton of Basel-City 4031

  1 trial

  • NCT07166549Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)

    Contact: Andreas Holbro, Prof. Dr.

• University Hospital Basel, Division of Nuclear Medicine

  Basel, 4031

  1 trial

  • NCT04909333Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia

• University Hospital Basel, Division of Outpatient Cardiology

  Basel, 4031

  1 trial

  • NCT05500859Swiss Secondary Prevention and Rehabilitation Registry

    Contact: Otmar Pfister, Prof. Dr. med.

• University Hospital Basel, Heart Center

  Basel, 4053

  1 trial

  • NCT04881578Atrial Fibrillation Before and After Patent Foramen Ovale Closure Study

• University Hospital Basel, Hepatology Department and Laboratory

  Basel, 4031

  1 trial

  • NCT04116242MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease

• University Hospital Basel /ID# 161732

  Basel Town, Canton of Basel-City 4031

  1 trial

  • NCT03006068A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

• University Hospital Basel /ID# 164554

  Basel Town, Canton of Basel-City 4031

  1 trial

  • NCT03105102A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

• University Hospital Basel /ID# 212744

  Basel Town, Canton of Basel-City 4031

  1 trial

  • NCT03982394Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis

• University Hospital Basel /ID# 223711

  Basel Town, Canton of Basel-City 4031

  1 trial

  • NCT04524611Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

• University Hospital Basel /ID# 230977

  Basel Town, Canton of Basel-City 4031

  1 trial

  • NCT03539536Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

• University Hospital Basel /ID# 252907

  Basel Town, Canton of Basel-City 4031

  1 trial

  • NCT05843643Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

• University Hospital Basel /ID# 264245

  Basel Town, Canton of Basel-City 4031

  1 trial

  • NCT06468228A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

• University Hospital Basel /ID# 276716

  Basel Town, Canton of Basel-City 4031

  1 trial

  • NCT07136467A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa

    Contact: Beth Rycroft

• University Hospital Basel /ID# 280787

  Basel Town, Canton of Basel-City 4031

  1 trial

  • NCT07365241A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

• University Hospital Basel (Site 0709)

  Basel, Canton of Basel-City 4056

  1 trial

  • NCT03867084Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

• University Hospital Basel (Site 0859)

  Basel, Canton of Basel-City 4031

  1 trial

  • NCT06925737A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

    Contact: Study Coordinator

• University Hospital Basel (Site 1102)

  Basel, Canton of Basel-City 4031

  1 trial

  • NCT07044297A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

• University Hospital Basel (Site 2205)

  Basel, Canton of Basel-City 4031

  1 trial

  • NCT05612035Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

• University Hospital Basel, Stroke Center

  Basel, 4031

  1 trial

  • NCT06258109Risk of Recurrent CeAD After Pregnancy

    Contact: Stefan T Engelter, MD

• University Hospital Basel, Urology

  Basel, Canton of Basel-City 4031

  1 trial

  • NCT07762911Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year Follow-up Round (VISIONING III)

    Contact: Cyrill Rentsch, Prof

• University Hospital in Basel

  Basel, Basel-Stadt (de) 4031

  1 trial

  • NCT02598661Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

• University Hospital of Basel Department of Oncology

  Basel, 04031

  1 trial

  • NCT04680052A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.